AstraZeneca Withdraws Iressa Accelerated Approval NDA; Rules out Refiling with PGx Data

Feb 09, 2011

Premium

AstraZeneca announced earlier this month that it will not seek approval from the US Food and Drug Administration for its EGFR tyrosine kinase inhibitor Iressa as a treatment for non-small cell lung cancer.

"AstraZeneca does not plan to pursue approval for Iressa in the US," the company said in a statement. Furthermore, AstraZeneca has informed the FDA that it will be withdrawing its accelerated approval new drug application for Iressa as of Sept. 30.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Featured White Papers

STARLIMS Quality Manufacturing Solution Interfacing with 3rd party systems

STARLIMS Biorepository Solution Helps Fortune 200 Company Boost Efficiency, Cost Effectiveness, And Increase Sample Management By 25 Percent

ABBOTT Informatics STARLIMS Solution Helps Precision Diagnostics Achieve Compliance and Retain Customers

Meeting Modern Data Integrity and Compliance Requirements

Jun

14

Featured Webinar

Overcoming Challenges in Hematological Genomic Testing with Advanced AI

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

20

Featured Webinar

Expert Tips on Sequencing and Library Prep from the Wellcome Sanger Institute

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun

28

Featured Webinar

An Optimized NGS Workflow for Human Metagenomic Analysis

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Main menu